PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8239936

A method for detecting variability arising from errors in sample processing of paraffin-embedded tissue for DNA content analysis.

J B Hendricks·N S Hardt·E J Wilkinson·P G Pharis·R C Braylan
View original source ↗Export metadata ↓

Abstract

We present a method for controlling variability that may arise from inconsistencies in sample preparation for DNA content analysis of paraffin-embedded tissue. Human tonsil tissue obtained from routine surgical specimens was embedded in paraffin according to standard protocols. Fifty-micrometer sections were cut from the block and analyzed each day for 20 days to establish control ranges. One tonsil tissue section was processed in parallel with each run of clinical specimens. In this context, a run was defined as the simultaneous processing of 50-microns tissue sections for extraction of cell nuclei (dewaxing and rehydrating). If the tonsil G0/G1 peak coefficient of variation (CV) exceeded 2 SDs of the established mean, and optimum instrument performance and staining were verified, all samples prepared with the tonsil control were reprocessed. Instrument performance and staining were assessed by using the appropriate external controls. By using this rejection rule (12s), the frequency of sample reprocessing in our laboratory was approximately 6%. When the run was repeated and the tonsil control CV was within acceptable range, the G0/G1 peak CV of the corresponding clinical specimens improved 25% of the time. Because most investigators are willing to accept higher CVs for paraffin-embedded tissue than for fresh tissue, it is desirable to have a control to detect decreased peak resolution, resulting from errors in sample processing.

Explore related subjects

Cell NucleusDNAFemaleFlow CytometryHumansOvarian NeoplasmsPalatine TonsilParaffin EmbeddingQuality ControlSpecimen HandlingJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J B Hendricks, N S Hardt, E J Wilkinson, P G Pharis, R C Braylan. 1993. A method for detecting variability arising from errors in sample processing of paraffin-embedded tissue for DNA content analysis.. https://pubmed.ncbi.nlm.nih.gov/8239936/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

Decoding ALS from the tail end of RNA.

In this issue of Cell Genomics, McKeever et al.1 generate a single-nucleus transcriptomic atlas of ALS/FTLD brain and reveal widespread alternative polyadenylation changes. Their findings highlight 3' end RNA processing as a central integrator of stress responses, cell-type specificity, and disease susceptibility, offering new mechanistic insight and potential therapeutic directions.

Cell Nucleus↗
PubMed1996

Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4.

In response to interferon-gamma (IFN-gamma), Stat1 enters the nucleus, where it activates transcription. In order to better understand the mechanism of the extracellular signal-induced protein import into the nucleus, we have established an in vivo assay system that uses recombinant Stat1 protein as a model transport substrate. Using this system, we found that Stat1 is actively transported through the nuclear pores in an IFN-gamma-dependent manner and tyrosine (Tyr701) phosphorylation of Stat1 is actually required for its nuclear import. When the antibody against Ran, which was identified as an essential factor for active nuclear protein transport, was injected, the IFN-gamma-dependent nuclear transport of Stat1 was completely inhibited. Furthermore, nuclear import of Stat1 was suppressed by microinjection of two mutant Ran proteins, one defective in GTP hydrolysis (G19V) and the other with little or no binding to GTP (T24N), both of which are known to act as dominant negative inhibitors of nuclear import. These results indicate that the conditional nuclear import of Stat1 requires GTP hydrolysis by Ran.

Cell Nucleus↗
PubMed1996

PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components.

The PML protein is a human growth suppressor concentrated in 10 to 20 nuclear bodies per nucleus (PML bodies). Disruption of the PML gene has been shown to be related to acute promyelocytic leukaemia (APL). To obtain information about the function of PML bodies we have investigated the 3D-distribution of PML bodies in the nucleus of T24 cells and compared it with the spatial distribution of a variety of other nuclear components, using fluorescence dual-labeling immunocytochemistry and confocal microscopy. Results show that PML bodies are not enriched in nascent RNA, the splicing component U2-snRNP, or transcription factors (glucocorticoid receptor, TFIIH, and E2F). These results show that PML bodies are not prominent sites of RNA synthesis or RNA splicing. We found that a large fraction of PML bodies (50 to 80%) is closely associated with DNA replication domains during exclusively middle-late S-phase. Furthermore, in most cells that we analysed we found at least one PML body was tightly associated with a coiled body. In the APL cell line NB4, the PML gene is fused with the RAR alpha gene due to a chromosomal rearrangement. PML bodies have disappeared and the PML antigen, i.e., PML and the PML-RAR fusion protein, is dispersed in a punctated pattern throughout the nucleoplasm. We showed that in NB4 cells the sites that are rich in PML antigen significantly colocalize with sites at which nascent RNA accumulates. This suggests that, in contrast to non-APL cells, in NB4 cells the PML antigen is associated with sites of transcription. The implications of these findings for the function of PML bodies are consistent with the idea that PML bodies are associated with specific genomic loci.

Cell Nucleus↗